This study is the first Phase III trial to demonstrate the efficacy of a medical therapy for Cushing’s disease, which is a debilitating endocrine disorder caused by excess
APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases. As per the agreement, GDBP will have an exclusive license
AIT, a dissolvable oral tablet is being studied to determine whether AIT may help to prevent allergy symptoms by stimulating an immune response against targeted allergens. Phase III
The new production line will produce Paclitaxel, a chemotherapy agent inhibiting proliferation of cancer cells used in the treatment of patients with breast, ovarian and non-small cell lung
The calcium in Xtra-Cal helps maintain strong, healthy bones and teeth while the magnesium and vitamin D present in the product enable improved calcium absorption. Xtra-Cal consumption will
According to the study data, 74% (28 out of 38) of patients who were treated with Incivek combination therapy had undetectable hepatitis C virus (HCV RNA) 12 weeks
Surfaxin (lucinactant intratracheal suspension) is a synthetic, peptide-containing surfactant, indicated for use in premature infants at high risk for RDS. Discovery Labs chief executive officer and chairman of
Amitiza is indicated for the treatment of chronic idiopathic constipation and for IBS-C. The open-label extension Phase 3 study was conducted by Takeda Pharmaceuticals USA, and Sucampo Pharmaceuticals
The LyoCell technology allows for the solubilization, stabilization, and delivery of a wide range of compounds – both small and large molecule. As per the agreement, PSI obtains
Marshall Edwards is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. Marshall Edwards president and chief executive officer Daniel Gold expressed satisfaction
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.